Not the greatest quarterly... IBN at these levels has a lot of negatives priced in, large future receivables book and a new CEO. Hopefully these factors can see us hit a good Q2FY19.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025